United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (germany) - propafenone hydrochloride - solution for injection - 3.5mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - propafenone hydrochloride 150mg;  ;  ; propafenone hydrochloride 150mg - tablet - 150 mg - active: propafenone hydrochloride 150mg     excipient: croscarmellose sodium hypromellose   macrogol 400 macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide active: propafenone hydrochloride 150mg excipient: croscarmellose sodium hypromellose   macrogol 400 macrogol 6000 magnesium stearate microcrystalline cellulose pregelatinised maize starch purified water titanium dioxide - for the treatment of supraventricular extrasystoles and supraventricular tachycardias, and in wolff-parkinson-white (wpw) syndrome. also for the treatment of life-threatening documented ventricular tachyarrhythmia. the use of rytmonorm is not recommended in patients with less severe ventricular arrhythmias, even if the patients are symptomatic. because of the proarrhythimic effects of rytmonorm, its use should be reserved for patients in whom, in the opinion of the physician, the potential benefits of treatment outweigh the risks.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - propafenone hydrochloride 300mg - tablet - 300 mg - active: propafenone hydrochloride 300mg excipient: croscarmellose sodium hypromellose   macrogol 400 macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide - for the prophylaxis and treatment of supraventricular extrasystoles and supraventricular tachycardias, and in wpw syndrome. also for the prophylaxis and treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia. the use of rytmonorm is not recommended in patients with less severe ventricular arrhythmias, even if the patients are symptomatic. because of the proarrhythimic effects of rytmonorm, its use should be reserved for patients in whom, in the opinion of the physician, the potential benefits of treatment outweigh the risks.

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - propafenone hcl - tablet, film coated - 150 mg - propafenone hcl 150 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbott laboratories (m) sdn. bhd. - propafenone hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - propafenone hydrochloride -

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - propafenone hydrochloride - film coated tablets - propafenone hydrochloride 150 mg - antiarrhythmics, class ic - prophylaxis and treatment of ventricular arrhythmias. prophylaxis and treatment of atrial fibrillation and flutter. prophylaxis and treatment of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms.